AAMC is mentioned in a recent Consumer Reports article, which provides guidelines for patients on choosing a hospital for surgery.
News You Can Use
ASCO Special Article: Use of pharmacologic interventions for breast cancer risk reduction: ASCO practice guidelineby jmiller on July 15, 2013
This early release article (JCO early release) includes the specific risks and benefits associated with each chemopreventive agent. In women at increased risk of BC age >35 years, tamoxifen (20 mg per day for 5 years) should be discussed as an option to reduce the risk of ER – positive BC. In postmenopausal women, raloxifene (60 mg per day for 5 years) should also be discussed as options for BC risk reduction. These guideline recommendations are for use by medical oncologists, surgical oncologists, gynecologists, primary care physicians, and general practitioners. Click here to read full-text.
“Our work has focused on identifying the relationship of the insulin network to brain aging, and determining the mechanisms through which insulin dysregulation promotes AD pathological processes. Fortunately, insulin resistance and related factors can be identified prior to the onset of AD, at a stage where lifestyle modifications or therapeutic intervention may have the greatest likelihood of success.” (Journal of Alzheimer’s Disease, June 2013) Click here to read full-text.
“The authors have developed 7 recommendations to improve patient safety with respect to the deployment of EDIS’s (Emergency Dept. Information Systems). These include ensuring that emergency providers actively participate in selection of the EDIS product, in the design of processes related to EDIS implementation and optimization, and in the monitoring of the system’s ongoing success or failure. Our recommendations apply to emergency departments using any type of EDIS: custom- developed systems, best-of-breed vendor systems, or enterprise systems.” (Ann Intern Med, in press) Click here to read full-text.
Effective Monday, July 1, Dr. Khalid Ahmed will be available for Inpatient and Emergency Department psychiatric consultation.
Dr. Ahmed has extensive experience in the acute management of adult and pediatric psychiatric patients. For the last year, he has worked at Dorchester General and Adventist Behavioral Health. Dr. Ahmed completed his residency in child and adolescent psychiatry at Johns Hopkins University Hospital and his residency in general psychiatry at Drexel University College of Medicine. He is ABPN certified with a subspecialty in child & adolescent psychiatry.
Dr. Ahmed will be available from 8am until 4pm five (5) days each week to include a rotation to the weekends. Beginning on Monday, he can be reached via phone at extension 3767 or by placing a clinical consultation request for psychiatry in EPIC. For days that he is not on campus, Behavioral Health Clinicians will continue to be available to address immediate patient needs.
This “in press” article (Ann Emerg Med) is a joint effort of members of the Quality Improvement and Patient Safety Section and the Informatics Section of the American College of Emergency Physicians to examine the benefits and potential threats to quality and patient safety that could result from the choice of a particular EDIS, its implementatiion and optimization, and the hospital’s or physician group’s approach to continuous improvement of the EDIS. “Specirically, we explored the following areas of potential EDIS concerns: communication failure, wrong order-wrong patient errors, poor data display, and alert fatigue. The authors have developed 7 recommendations to improve patient safety with respect to the deployment of EDISs. Click here to read full text.
Effectiveness and harms of recombinant human bone morphogenic protein-2 in spine fusion: a systematic review and meta-analysisby jmiller on June 21, 2013
This is a “hot” topic in the orthopedic world… Article concludes: “In spinal fusion, rhBMP-2 has no proven clinical advantage over bone graft and may be associated with important harms, making it difficult to identify clear indications for rhBMP-w. Earlier disclosure of all relevant data would have better informaed clinicians and the public than the initial published trial reports did. (Ann Intern Med, June 18) Click here to read full-text.
Time to treatment with intravenous tissue plasminogen activator and outcome from acute ischemic strokeby jmiller on June 21, 2013
“In a registry representing US clinical practice, earlier thrombolytic treatment was associated with reduced mortality and symptomatic intracranial hemorrhage, and higher rates of independent ambulation at discharge and discharge to home following acute ischemic stroke. These finding support intensive efforts to accelerate hospital presentation and thrombolytic treatment in patients with stroke. (JAMA, June 16) Click here to read full text.